(Q38233326)

31 August 2017

Optimal treatment for metastatic bladder cancer (English)

1 reference

31 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25056737%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Estrella M Carballido

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25056737%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

1 September 2014

1 reference

31 August 2017

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25056737%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25056737%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

404

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25056737%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25056737%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-014-0404-2

13 June 2020

exact match

0 references

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

A Phase II study of oxaliplatin in urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Oncogenic FGFR3 gene fusions in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0404-2

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

21 January 2018

1 reference

12 December 2020

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

1 reference

12 December 2020

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

12 December 2020

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

1 reference

12 December 2020

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

12 December 2020

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

12 December 2020

Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis

1 reference

12 December 2020

Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma

1 reference

12 December 2020

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

1 reference

12 December 2020

A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.

1 reference

12 December 2020

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function

1 reference

12 December 2020

HER-2--a possible target for therapy of metastatic urinary bladder carcinoma

1 reference

12 December 2020

Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer

1 reference

12 December 2020

Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer

1 reference

12 December 2020

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

12 December 2020

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

12 December 2020

Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.

1 reference

12 December 2020

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

12 December 2020

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

12 December 2020

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

12 December 2020

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy

1 reference

12 December 2020